These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 6776977)

  • 1. Potential therapeutic applications of aspirin and other cyclo-oxygenase inhibitors.
    Farah AE; Rosenberg F
    Br J Clin Pharmacol; 1980 Oct; 10 Suppl 2(Suppl 2):261S-278S. PubMed ID: 6776977
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparison of the effects of a thromboxane antagonist and cyclo-oxygenase inhibitor on platelet accumulation in arterial grafts.
    Lane I; Meek A; Poskitt K; McCollum C
    Prog Clin Biol Res; 1987; 242():409-12. PubMed ID: 3118388
    [No Abstract]   [Full Text] [Related]  

  • 3. Thromboxane (Tx) A2 receptor blockade and TxA2 synthase inhibition alone and in combination: comparison of anti-aggregatory efficacy in human platelets.
    Watts IS; Wharton KA; White BP; Lumley P
    Br J Pharmacol; 1991 Feb; 102(2):497-505. PubMed ID: 1826620
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Renal effects of nonsteroidal anti-inflammatory drugs in chronic glomerular disease.
    Patrono C; Pierucci A
    Am J Med; 1986 Aug; 81(2B):71-83. PubMed ID: 3092667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathophysiologic roles of prostaglandins and the action of aspirin-like drugs.
    Nakano J; Koss MC
    South Med J; 1973 Jun; 66(6):709-23. PubMed ID: 4575324
    [No Abstract]   [Full Text] [Related]  

  • 6. The role of prostacyclin in vascular tissue.
    Moncada S; Vane JR
    Fed Proc; 1979 Jan; 38(1):66-71. PubMed ID: 215463
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential inhibition by aspirin of platelet thromboxane and renal prostaglandins in the rat.
    Livio M; Benigni A; Zoja C; Begnis R; Morelli C; Rossini M; Garattini S; Remuzzi G
    J Pharmacol Exp Ther; 1989 Jan; 248(1):334-41. PubMed ID: 2492341
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Triggering by Paf-acether and adrenaline of cyclo-oxygenase-independent platelet aggregation.
    Fouque F; Vargaftig BB
    Br J Pharmacol; 1984 Nov; 83(3):625-33. PubMed ID: 6439269
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antithrombotic effects of drugs which suppress platelet function: their potential in prevention growth of tumour cells.
    Turpie AG
    Prog Clin Biol Res; 1982; 89():31-62. PubMed ID: 7051035
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biologic interaction of prostaglandin, thromboxane and prostacyclin: potential clinical applications.
    Bell TG; Smith WL; Oxender WD
    J Environ Pathol Toxicol Oncol; 1986; 6(3-4):191-201. PubMed ID: 3012063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thromboxane A2/prostaglandin H2 receptor antagonists. A new therapeutic principle.
    Patscheke H
    Stroke; 1990 Dec; 21(12 Suppl):IV139-42. PubMed ID: 2148033
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms of aspirin resistance.
    Floyd CN; Ferro A
    Pharmacol Ther; 2014 Jan; 141(1):69-78. PubMed ID: 23993980
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of aspirin on hemostasis and thrombosis.
    Buchanan MR; Hirsh J
    N Engl Reg Allergy Proc; 1986; 7(1):26-31. PubMed ID: 3302653
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Aspirin resistance: position paper of the working group on aspirin resistance of the international society on thrombosis and haemostasis].
    Boskholov BP
    Kardiologiia; 2005; 45(7):75-6. PubMed ID: 16091668
    [No Abstract]   [Full Text] [Related]  

  • 15. Prostaglandins and vascular function.
    Weksler BB
    Circulation; 1984 Nov; 70(5 Pt 2):III63-71. PubMed ID: 6386223
    [No Abstract]   [Full Text] [Related]  

  • 16. Homocysteine is a novel risk factor for suboptimal response of blood platelets to acetylsalicylic acid in coronary artery disease: a randomized multicenter study.
    Karolczak K; Kamysz W; Karafova A; Drzewoski J; Watala C
    Pharmacol Res; 2013 Aug; 74():7-22. PubMed ID: 23665469
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Failure of cyclo-oxygenase inhibition to protect against arrhythmias induced by ischaemia and reperfusion: implications for the role of prostaglandins as endogenous myocardial protective substances.
    Wainwright CL; Parratt JR
    Cardiovasc Res; 1991 Feb; 25(2):93-100. PubMed ID: 1742769
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Pharmacology of anti-platelet agents].
    Lecompte T; Kher A; Gaillard JL; Samama M
    J Mal Vasc; 1983; 8(1):3-16. PubMed ID: 6302191
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostacyclin: a hormone with a therapeutic potential. The Sir Henry Dale Lecture for 1981.
    Vane JR
    J Endocrinol; 1982 Nov; 95(2):3P-43P. PubMed ID: 6816886
    [No Abstract]   [Full Text] [Related]  

  • 20. Antiplatelet effect of aspirin in patients with coronary artery disease.
    Grove EL
    Dan Med J; 2012 Sep; 59(9):B4506. PubMed ID: 22951204
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.